Protein engineering and preclinical development of a GM-CSF receptor antibody for the treatment of rheumatoid arthritis. 2013

R R Minter, and E S Cohen, and B Wang, and M Liang, and I Vainshtein, and G Rees, and L Eghobamien, and P Harrison, and D A Sims, and C Matthews, and T Wilkinson, and P Monk, and C Drinkwater, and L Fabri, and A Nash, and M McCourt, and L Jermutus, and L Roskos, and I K Anderson, and M A Sleeman
Research, MedImmune Ltd, Cambridge, UK.

OBJECTIVE For antibody therapies against receptor targets, in vivo outcomes can be difficult to predict because of target-mediated clearance or antigen 'sink' effects. The purpose of this work was to engineer an antibody to the GM-CSF receptor α (GM-CSFRα) with pharmacological properties optimized for chronic, s.c. treatment of rheumatoid arthritis (RA) patients. METHODS We used an in silico model of receptor occupancy to guide the target affinity and a combinatorial phage display approach for affinity maturation. Mechanism of action and internalization assays were performed on the optimized antibody in vitro before refining the modelling predictions of the eventual dosing in man. Finally, in vivo pharmacology studies in cynomolgus monkeys were carried out to inform the predictions and support future clinical development. RESULTS Antibody potency was improved 8600-fold, and the target affinity was reached. The refined model predicted pharmacodynamic effects at doses as low as 1 mg kg(-1) and a study in cynomolgus monkeys confirmed in vivo efficacy at 1 mg kg(-1) dosing. CONCLUSIONS This rational approach to antibody drug discovery enabled the isolation of a potent molecule compatible with chronic, s.c. self-administration by RA patients. We believe this general approach enables the development of optimal biopharmaceuticals.

UI MeSH Term Description Entries
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D008252 Macaca fascicularis A species of the genus MACACA which typically lives near the coast in tidal creeks and mangrove swamps primarily on the islands of the Malay peninsula. Burmese Long-Tailed Macaque,Crab-Eating Monkey,Cynomolgus Monkey,M. f. aurea,M. fascicularis,Macaca fascicularis aurea,Monkey, Crab-Eating,Monkey, Cynomolgus,Crab-Eating Macaque,Burmese Long Tailed Macaque,Crab Eating Macaque,Crab Eating Monkey,Crab-Eating Macaques,Crab-Eating Monkeys,Cynomolgus Monkeys,Long-Tailed Macaque, Burmese,Macaque, Burmese Long-Tailed,Macaque, Crab-Eating,Monkey, Crab Eating
D008297 Male Males
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000906 Antibodies Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).

Related Publications

R R Minter, and E S Cohen, and B Wang, and M Liang, and I Vainshtein, and G Rees, and L Eghobamien, and P Harrison, and D A Sims, and C Matthews, and T Wilkinson, and P Monk, and C Drinkwater, and L Fabri, and A Nash, and M McCourt, and L Jermutus, and L Roskos, and I K Anderson, and M A Sleeman
October 2015, Annals of the rheumatic diseases,
R R Minter, and E S Cohen, and B Wang, and M Liang, and I Vainshtein, and G Rees, and L Eghobamien, and P Harrison, and D A Sims, and C Matthews, and T Wilkinson, and P Monk, and C Drinkwater, and L Fabri, and A Nash, and M McCourt, and L Jermutus, and L Roskos, and I K Anderson, and M A Sleeman
November 1993, Lancet (London, England),
R R Minter, and E S Cohen, and B Wang, and M Liang, and I Vainshtein, and G Rees, and L Eghobamien, and P Harrison, and D A Sims, and C Matthews, and T Wilkinson, and P Monk, and C Drinkwater, and L Fabri, and A Nash, and M McCourt, and L Jermutus, and L Roskos, and I K Anderson, and M A Sleeman
June 2017, Annals of the rheumatic diseases,
R R Minter, and E S Cohen, and B Wang, and M Liang, and I Vainshtein, and G Rees, and L Eghobamien, and P Harrison, and D A Sims, and C Matthews, and T Wilkinson, and P Monk, and C Drinkwater, and L Fabri, and A Nash, and M McCourt, and L Jermutus, and L Roskos, and I K Anderson, and M A Sleeman
January 2016, Clinical and experimental rheumatology,
R R Minter, and E S Cohen, and B Wang, and M Liang, and I Vainshtein, and G Rees, and L Eghobamien, and P Harrison, and D A Sims, and C Matthews, and T Wilkinson, and P Monk, and C Drinkwater, and L Fabri, and A Nash, and M McCourt, and L Jermutus, and L Roskos, and I K Anderson, and M A Sleeman
December 2012, Expert opinion on biological therapy,
R R Minter, and E S Cohen, and B Wang, and M Liang, and I Vainshtein, and G Rees, and L Eghobamien, and P Harrison, and D A Sims, and C Matthews, and T Wilkinson, and P Monk, and C Drinkwater, and L Fabri, and A Nash, and M McCourt, and L Jermutus, and L Roskos, and I K Anderson, and M A Sleeman
August 1991, Lancet (London, England),
R R Minter, and E S Cohen, and B Wang, and M Liang, and I Vainshtein, and G Rees, and L Eghobamien, and P Harrison, and D A Sims, and C Matthews, and T Wilkinson, and P Monk, and C Drinkwater, and L Fabri, and A Nash, and M McCourt, and L Jermutus, and L Roskos, and I K Anderson, and M A Sleeman
October 2009, Nature reviews. Rheumatology,
R R Minter, and E S Cohen, and B Wang, and M Liang, and I Vainshtein, and G Rees, and L Eghobamien, and P Harrison, and D A Sims, and C Matthews, and T Wilkinson, and P Monk, and C Drinkwater, and L Fabri, and A Nash, and M McCourt, and L Jermutus, and L Roskos, and I K Anderson, and M A Sleeman
March 2021, Expert opinion on drug discovery,
R R Minter, and E S Cohen, and B Wang, and M Liang, and I Vainshtein, and G Rees, and L Eghobamien, and P Harrison, and D A Sims, and C Matthews, and T Wilkinson, and P Monk, and C Drinkwater, and L Fabri, and A Nash, and M McCourt, and L Jermutus, and L Roskos, and I K Anderson, and M A Sleeman
April 2020, Journal of molecular medicine (Berlin, Germany),
R R Minter, and E S Cohen, and B Wang, and M Liang, and I Vainshtein, and G Rees, and L Eghobamien, and P Harrison, and D A Sims, and C Matthews, and T Wilkinson, and P Monk, and C Drinkwater, and L Fabri, and A Nash, and M McCourt, and L Jermutus, and L Roskos, and I K Anderson, and M A Sleeman
October 2017, Clinical reviews in allergy & immunology,
Copied contents to your clipboard!